LAMA/LABA Combo Duaklir Moves Closer To US Filing

 
• By John Davis

AstraZeneca has released positive top-line data from a new Phase III study of the LAMA/LABA combination, Duaklir, in COPD that could lead to a US NDA filing in 2018, and the start of US marketing by partner Circassia.

Blue sky
Clean air is important for COPD patients. • Source: Shutterstock

More from Clinical Trials

More from R&D